Paradoxical response to osimertinib therapy in a patient with T790M‑mutated lung adenocarcinoma

Okauchi,Shinichiro; Osawa,Hajime; Miyazaki,Kunihiko; Kawaguchi,Mio; Satoh,Hiroaki

doi:10.3892/mco.2017.1474

January-2018 Volume 8 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2018 Volume 8 Issue 1

Full Size Image

Article

Paradoxical response to osimertinib therapy in a patient with T790M‑mutated lung adenocarcinoma

Authors:
- Shinichiro Okauchi
- Hajime Osawa
- Kunihiko Miyazaki
- Mio Kawaguchi
- Hiroaki Satoh
View Affiliations / Copyright

Affiliations: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan, Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan
Pages: 175-177
|
Published online on: October 27, 2017

https://doi.org/10.3892/mco.2017.1474
Expand metrics +

Abstract

A ‘paradoxical response’ to cancer treatment is a term used to describe the emergence of unexpected new lesions and the progression of existing lesions, despite appropriate and effective therapy. ‘Pseudo‑progression’ is a phenomenon in which lymphocytes activated by an immune checkpoint inhibitor accumulate in a tumor and expand its shadow, mimicking enlargement of the primary lesion or development of a new metastatic lesion. Patients receiving cancer chemotherapy may respond differently to treatment, by exhibiting a response, deterioration, or the simultaneous occurrence of both. These variations may be attributed to the heterogeneity of the cancer. However, differences in the temporary response to epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI) treatment are rarely observed. If such a phenomenon is observed, it should not affect the evaluation of the therapeutic effect or be considered as an indication for the discontinuation of treatment. We herein report a rare case of a transient increase in carcinomatous pleural fluid as a paradoxical response to osimertinib treatment in a patient with T790M‑mutated lung adenocarcinoma. The primary lesion and pulmonary metastases responded well to therapy. Although this paradoxical response is very rare, of non‑malignant nature, and does not usually require treatment modification of, physicians must acknowledge that it is not a clinically discouraging characteristic when using EGFR‑TKI to treat T790M‑mutated lung adenocarcinoma.

View Figures

View References

1	Breen RA, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA and Lipman MC: Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 59:704–707. 2004. View Article : Google Scholar : PubMed/NCBI
2	Marshall BG and Chambers MA: Central nervous system tuberculosis-the paradox of the host immune response. J Infect. 36:3–4. 1998. View Article : Google Scholar : PubMed/NCBI
3	Gupta RC, Dixit R, Purohit SD and Saxena A: Development of pleural effusion in patients during anti-tuberculosis therapy: Analysis of twenty-nine cases with review of literature. Indian J Chest Dis Allied Sci. 42:161–166. 2000.PubMed/NCBI
4	Bukharie H: Paradoxical response to anti-tuberculosis drugs: Resolution with corticosteroid therapy. Scand J Infect Dis. 32:96–97. 2000. View Article : Google Scholar : PubMed/NCBI
5	Al-Orainey IO: Diagnosis of latent tuberculosis: Can we do better? Ann Thorac Med. 4:5–9. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ito K, Hataji O, Katsuta K, Kobayashi T, Gabazza EC, Yatabe Y, Taguchi O and Yamamoto N: ‘Pseudoprogression’ of pulmonary pleomorphic carcinoma during nivolumab therapy. J Thorac Oncol. 11:e117–e119. 2016. View Article : Google Scholar : PubMed/NCBI
7	Kolla BC and Patel MR: Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. J Immunother Cancer. 4:802016. View Article : Google Scholar : PubMed/NCBI
8	Tanizaki J, Hayashi H, Kimura M, Tanaka K, Takeda M, Shimizu S, Ito A and Nakagawa K: Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer. 102:44–48. 2016. View Article : Google Scholar : PubMed/NCBI
9	Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M and Maio M: Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 58:1297–1306. 2009. View Article : Google Scholar : PubMed/NCBI
10	Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, et al: A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 30:1–15. 2007. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Paradoxical response to osimertinib therapy in a patient with T790M‑mutated lung adenocarcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles